Н.В. Куркина и др.
КЛИНИЧЕСКАЯ ОНКОГЕМАТОЛОГИЯ
20.
Ganz T, Nemeth E. Iron sequestration and anemia of infl ammation. Semin
Hematol. 2009;46(4):387–393. doi: 10.1053/j.seminhematol.2009.06.001.
21.
Морщакова Е.Ф., Павлов А.Д., Румянцев А.Г. Эритропоэз, эритропо-
этин, железо. М.: ГЭОТАР-Медиа, 2013. 178 с.
[Morshchakova EF, Pavlov AD, Rumyantsev AG. Eritropoez, eritropoetin,
zhelezo. (Erythropoiesis, erythropoietin, iron.) Moscow: GEOTAR-Media Publ.;
2013. 178 p. (In Russ)]
22.
Рукавицын О.А. Анемия хронических заболеваний: отдельные
аспекты патогенеза и пути коррекции. Онкогематология. 2016;11(1):37–46.
doi: 10.17650/1818-8346-2016-11-1-37-46.
[Rukavitsyn OA. Anemia of chronic diseases: the important aspects of patho-
genesis and treatment. Oncohematology. 2016;11(1):37–46. doi: 10.17650/1818-
8346-2016-11-1-37-46. (In Russ)]
23.
Румянцев А.Г., Масчан А.А. Федеральные клинические рекомен-
дации по диагностике и лечению анемии хронических заболеваний
(электронный документ). Доступно по: https://nodgo.org/sites/default/
files/%D0%A4%D0%9A%D0%A0%20%D0%BF%D0%BE%20%D0%B4%D
0 % B 8 % D 0 % B 0 % D 0 % B 3 % D 0 % B D % D 0 % B E % D 1 % 8 1 % D 1 % 8 2 % D 0 % B 8 % D
0 % B A % D 0 % B 5 % 2 0 % D 0 % B 8 % 2 0 % D 0 % B B % D 0 % B 5 % D 1 % 8 7 % D 0 % B 5 % -
D0%BD%D0%B8%D1%8E%20%D0%B0%D0%BD%D0%B5%D0%BC%D0%B
8%D0%B8%20%D1%85%D1%80%D0%BE%D0%BD%D0%B8%D1%87%D0%
B5%D1%81%D0%BA%D0%B8%D1%85%20%D0%B1%D0%BE%D0%BB%D0%-
B5%D0%B7%D0%BD%D0%B5%D0%B9.pdf. Ссылка активна на 13.04.2021.
[Rumyantsev AG, Maschan AA. Federal clinical guidelines for diagnosis
and treatment of anemia of chronic diseases. [Internet] Available from:
h t t p s : / / n o d g o . o r g / s i t e s / d e f a u l t / f i l e s / % D 0 % A 4 % D 0 % 9 A % D 0 % A 0 % 2 0
% D 0 % B F % D 0 % B E % 2 0 % D 0 % B 4 % D 0 % B 8 % D 0 % B 0 % D 0 % B 3 % D 0 % B -
D % D 0 % B E % D 1 % 8 1 % D 1 % 8 2 % D 0 % B 8 % D 0 % B A % D 0 % B 5 % 2 0
% D 0 % B 8 % 2 0 % D 0 % B B % D 0 % B 5 % D 1 % 8 7 % D 0 % B 5 % D 0 % B -
D % D 0 % B 8 % D 1 % 8 E % 2 0 % D 0 % B 0 % D 0 % B D % D 0 % B 5 % D 0 % B -
C % D 0 % B 8 % D 0 % B 8 % 2 0 % D 1 % 8 5 % D 1 % 8 0 % D 0 % B E % D 0 % B -
D % D 0 % B 8 % D 1 % 8 7 % D 0 % B 5 % D 1 % 8 1 % D 0 % B A % D 0 % B 8 % D 1 % 8 5 % 2 0
%D0%B1%D0%BE%D0%BB%D0%B5%D0%B7%D0%BD%D0%B5%D0%B9.pdf.
(accessed 13.04.2021) (In Russ)]
24.
Nemeth E, Ganz T. Anemia of Infl ammation. Hematol Oncol Clin North Am.
2014;28(4):671–81. doi: 10.1016/j.hoc.2014.04.005.
25.
Weiss G. Pathogenesis and treatment of anemia of chronic disease. Blood
Rev. 2002;16(2):87–96. doi: 10.1054/blre.2002.0193.
26.
Сморкалова Е.В. Иммуногематологические особенности железоде-
фицитной анемии и анемии хронических заболеваний: Автореф. дис. … канд.
мед. наук. Уфа, 2012. 22 с.
[Smorkalova EV. Immunogematologicheskie osobennosti zhelezodefi tsitnoi
anemii i anemii khronicheskikh zabolevanii. (Immunohematological characteris-
tics of iron defi ciency anemia and anemia of chronic diseases.) [dissertation] Ufa;
2012. 22 p. (In Russ)]
27.
Kato Y, Takagi C, Tanaka J, et al. Eff ect of daily subcutaneous administration
of recombinant erythropoietin on chronic anemia in rheumatoid arthritis. Intern
Med. 1994;33(4):193–7. doi: 10.2169/internalmedicine.33.193.
28.
Peeters HR, Jongen-Lavrencic M, Bakker CH, et al. Recombinant human
erythropoietin improves health-related quality of life in patients with rheumatoid
arthritis and anaemia of chronic disease; utility measures correlate strongly
with disease activity measures. Rheumatol Int. 1999;18(5–6):201–6. doi: 10.1007/
s002960050085.
29.
Arndt U, Kaltwasser JP, Gottschalk R, et al. Correction of iron-defi cient eryth-
ropoiesis in the treatment of anemia of chronic disease with recombinant human
erythropoietin. Ann Hematol. 2005;84(3):159–66. doi: 10.1007/s00277-004-0950-z.
30.
Schipperus M, Rijnbeek B, Reddy M, et al. CNTO328 (Anti-IL-6 mAb)
Treatment Is Associated with An Increase in Hemoglobin (Hb) and Decrease in
Hepcidin Levels in Renal Cell Carcinoma (RCC). Blood. 2009;114(22):4045. doi:
10.1182/blood.v114.22.4045.4045.
31.
Hohlbaum A, Gille H, Christian J, et al. Iron mobilization and pharmaco-
dynamic marker measurements in non-human primates following administration
of PRS-080, a novel and highly specifi c antihepcidin therapeutic. Am J Hematol.
2013;88(5):E41.
32.
Schwoebel F, van Eijk LT, Zboralski D, et al. The eff ects of the anti-hepcidin
Spiegelmer NOX-H94 on infl ammation-induced anemia in cynomolgus monkeys.
Blood. 2013;121(12):2311–5. doi: 10.1182/blood-2012-09-456756.
33.
Poli M, Girelli D, Campostrini N, et al. Heparin: a potent inhibitor of hepcidin
expression in vitro and in vivo. Blood. 2011;117(3):997–1004. doi: 10.1182/blood-
2010-06-2 89082.
34.
Crosby JR, Gaarde WA, Egerston J, et al. Targeting hepcidin with antisense
oligonucleotides improves anemia endpoints in mice. Blood. 2006;108(11, Pt
1):269. doi: 10.1182/blood.v108.11.269.269.
35.
Akinc A, Chan-Daniels A, Sehgal A, et al. Targeting the hepcidin pathway
with RNAi therapeutics for the treatment of anemia. Blood. 2011;118(21):688. doi:
10.1182/blood.v118.21.688.688.
36.
Гармиш Е.А. Анемия хронического воспаления при ревматоидном ар-
трите: патогенез и выбор терапии. Украинский ревматологический журнал.
2016;1(63):39–41.
[Garmish EА. Anemia of chronic infl
ammation of rheumatoid arthritis:
pathogenesis and choice of treatment. Ukrainskii revmatologicheskii zhurnal.
2016;1(63):39–41. (In Russ)]